25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CASI Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze CASI Pharmaceuticals Inc together

I guess you are interested in CASI Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of CASI Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about CASI Pharmaceuticals Inc

I send you an email if I find something interesting about CASI Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of CASI Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of CASI Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.19
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
$1.56
Expected worth in 1 year
$-9.50
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$-10.87
Return On Investment
-317.9%

For what price can you sell your share?

Current Price per Share
$3.42
Expected price per share
$2.05 - $5.2
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of CASI Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$3.42
Intrinsic Value Per Share
$-21.06 - $8.57
Total Value Per Share
$-19.49 - $10.14

2.2. Growth of CASI Pharmaceuticals Inc (5 min.)




Is CASI Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$24.1m$66.9m-$42.7m-177.0%

How much money is CASI Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$26.9m-$39.4m$12.4m46.3%
Net Profit Margin-79.5%-91.4%--

How much money comes from the company's main activities?

2.3. Financial Health of CASI Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#521 / 949

Most Revenue
#174 / 949

Most Profit
#740 / 949

Most Efficient
#427 / 949
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of CASI Pharmaceuticals Inc?

Welcome investor! CASI Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of CASI Pharmaceuticals Inc.

First you should know what it really means to hold a share of CASI Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of CASI Pharmaceuticals Inc is $3.42. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of CASI Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in CASI Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.56. Based on the TTM, the Book Value Change Per Share is $-2.77 per quarter. Based on the YOY, the Book Value Change Per Share is $-2.65 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.05 per quarter.
Based on historical numbers we can estimate the returns while holding a share of CASI Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.74-50.9%-1.74-50.9%-2.55-74.5%-2.55-74.6%-1.80-52.7%
Usd Book Value Change Per Share-2.77-80.9%-2.77-80.9%-2.65-77.6%-1.10-32.3%0.061.7%
Usd Dividend Per Share0.051.4%0.051.4%0.000.0%0.030.8%0.010.4%
Usd Total Gains Per Share-2.72-79.5%-2.72-79.5%-2.65-77.6%-1.08-31.5%0.072.1%
Usd Price Per Share7.16-7.16-1.79-3.16-2.65-
Price to Earnings Ratio-4.11--4.11--0.70--1.43--1.88-
Price-to-Total Gains Ratio-2.63--2.63--0.67-0.12-0.10-
Price to Book Ratio4.58-4.58-0.41-1.21--4.24-
Price-to-Total Gains Ratio-2.63--2.63--0.67-0.12-0.10-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.42
Number of shares292
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.050.03
Usd Book Value Change Per Share-2.77-1.10
Usd Total Gains Per Share-2.72-1.08
Gains per Quarter (292 shares)-793.76-314.24
Gains per Year (292 shares)-3,175.06-1,256.98
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
156-3231-318532-1289-1267
2112-6462-636064-2577-2524
3167-9692-953595-3866-3781
4223-12923-12710127-5155-5038
5279-16154-15885159-6444-6295
6335-19385-19060191-7732-7552
7390-22616-22235222-9021-8809
8446-25846-25410254-10310-10066
9502-29077-28585286-11599-11323
10558-32308-31760318-12887-12580

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.030.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%15.015.00.050.0%
Dividend per Share1.00.00.0100.0%1.00.02.033.3%3.00.02.060.0%3.00.07.030.0%4.00.026.013.3%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%15.015.00.050.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of CASI Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.766-2.7660%-2.654-4%-1.103-60%0.060-4737%
Book Value Per Share--1.5631.5630%4.329-64%5.126-70%3.613-57%
Current Ratio--3.5483.5480%4.318-18%5.917-40%10.028-65%
Debt To Asset Ratio--0.6790.6790%0.304+123%0.296+129%0.499+36%
Debt To Equity Ratio--2.1152.1150%0.657+222%0.710+198%0.409+417%
Dividend Per Share--0.0480.0480%-+100%0.027+75%0.014+251%
Enterprise Value--90367476.00090367476.0000%49710369.000+82%70311353.800+29%64756299.500+40%
Eps---1.742-1.7420%-2.549+46%-2.552+47%-1.801+3%
Ev To Ebitda Ratio---4.196-4.1960%-2.065-51%-2.592-38%-3.517-16%
Ev To Sales Ratio--2.6672.6670%1.153+131%6.632-60%infnan%
Free Cash Flow Per Share---1.436-1.4360%-1.727+20%-2.247+56%-1.602+12%
Free Cash Flow To Equity Per Share---1.495-1.4950%-1.938+30%-1.023-32%0.179-933%
Gross Profit Margin--1.6111.6110%1.364+18%1.310+23%1.155+39%
Intrinsic Value_10Y_max--8.575--------
Intrinsic Value_10Y_min---21.056--------
Intrinsic Value_1Y_max---1.074--------
Intrinsic Value_1Y_min---2.235--------
Intrinsic Value_3Y_max---1.753--------
Intrinsic Value_3Y_min---6.647--------
Intrinsic Value_5Y_max---0.656--------
Intrinsic Value_5Y_min---10.950--------
Market Cap52876962.000-109%110701476.000110701476.0000%27675369.000+300%48826153.800+127%40971915.000+170%
Net Profit Margin---0.795-0.7950%-0.914+15%-3.908+391%-127.490+15934%
Operating Margin---0.746-0.7460%-0.615-18%-2.495+234%-43.649+5750%
Operating Ratio--1.7961.7960%1.615+11%3.892-54%44.556-96%
Pb Ratio2.188-109%4.5814.5810%0.413+1008%1.212+278%-4.236+192%
Pe Ratio-1.963+52%-4.109-4.1090%-0.702-83%-1.426-65%-1.878-54%
Price Per Share3.420-109%7.1607.1600%1.790+300%3.158+127%2.650+170%
Price To Free Cash Flow Ratio-2.381+52%-4.985-4.9850%-1.037-79%-1.721-65%-2.682-46%
Price To Total Gains Ratio-1.258+52%-2.634-2.6340%-0.675-74%0.120-2304%0.101-2715%
Quick Ratio--3.2643.2640%4.030-19%5.922-45%9.762-67%
Return On Assets---0.358-0.3580%-0.410+14%-0.406+14%-0.641+79%
Return On Equity---1.115-1.1150%-0.884-21%-0.784-30%-0.490-56%
Total Gains Per Share---2.718-2.7180%-2.654-2%-1.076-60%0.073-3811%
Usd Book Value--24165000.00024165000.0000%66932000.000-64%79258800.000-70%55857070.400-57%
Usd Book Value Change Per Share---2.766-2.7660%-2.654-4%-1.103-60%0.060-4737%
Usd Book Value Per Share--1.5631.5630%4.329-64%5.126-70%3.613-57%
Usd Dividend Per Share--0.0480.0480%-+100%0.027+75%0.014+251%
Usd Eps---1.742-1.7420%-2.549+46%-2.552+47%-1.801+3%
Usd Free Cash Flow---22208000.000-22208000.0000%-26700000.000+20%-34745200.000+56%-24766785.600+12%
Usd Free Cash Flow Per Share---1.436-1.4360%-1.727+20%-2.247+56%-1.602+12%
Usd Free Cash Flow To Equity Per Share---1.495-1.4950%-1.938+30%-1.023-32%0.179-933%
Usd Market Cap52876962.000-109%110701476.000110701476.0000%27675369.000+300%48826153.800+127%40971915.000+170%
Usd Price Per Share3.420-109%7.1607.1600%1.790+300%3.158+127%2.650+170%
Usd Profit---26938000.000-26938000.0000%-39411000.000+46%-43619200.000+62%-29919998.900+11%
Usd Revenue--33879000.00033879000.0000%43107000.000-21%25285200.000+34%12649743.900+168%
Usd Total Gains Per Share---2.718-2.7180%-2.654-2%-1.076-60%0.073-3811%
 EOD+3 -5MRQTTM+0 -0YOY+20 -195Y+20 -1910Y+20 -18

3.3 Fundamental Score

Let's check the fundamental score of CASI Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.963
Price to Book Ratio (EOD)Between0-12.188
Net Profit Margin (MRQ)Greater than0-0.795
Operating Margin (MRQ)Greater than0-0.746
Quick Ratio (MRQ)Greater than13.264
Current Ratio (MRQ)Greater than13.548
Debt to Asset Ratio (MRQ)Less than10.679
Debt to Equity Ratio (MRQ)Less than12.115
Return on Equity (MRQ)Greater than0.15-1.115
Return on Assets (MRQ)Greater than0.05-0.358
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of CASI Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5023.758
Ma 20Greater thanMa 504.927
Ma 50Greater thanMa 1005.440
Ma 100Greater thanMa 2006.021
OpenGreater thanClose3.600
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About CASI Pharmaceuticals Inc

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-12-05 15:08:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit CASI Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare CASI Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -79.5% means that $-0.80 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of CASI Pharmaceuticals Inc:

  • The MRQ is -79.5%. The company is making a huge loss. -2
  • The TTM is -79.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-79.5%TTM-79.5%0.0%
TTM-79.5%YOY-91.4%+11.9%
TTM-79.5%5Y-390.8%+311.3%
5Y-390.8%10Y-12,749.0%+12,358.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-79.5%-112.2%+32.7%
TTM-79.5%-221.4%+141.9%
YOY-91.4%-210.0%+118.6%
5Y-390.8%-342.2%-48.6%
10Y-12,749.0%-464.5%-12,284.5%
4.3.1.2. Return on Assets

Shows how efficient CASI Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare CASI Pharmaceuticals Inc to the Biotechnology industry mean.
  • -35.8% Return on Assets means that CASI Pharmaceuticals Inc generated $-0.36 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of CASI Pharmaceuticals Inc:

  • The MRQ is -35.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -35.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-35.8%TTM-35.8%0.0%
TTM-35.8%YOY-41.0%+5.2%
TTM-35.8%5Y-40.6%+4.8%
5Y-40.6%10Y-64.1%+23.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-35.8%-11.3%-24.5%
TTM-35.8%-11.7%-24.1%
YOY-41.0%-11.3%-29.7%
5Y-40.6%-12.7%-27.9%
10Y-64.1%-14.1%-50.0%
4.3.1.3. Return on Equity

Shows how efficient CASI Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare CASI Pharmaceuticals Inc to the Biotechnology industry mean.
  • -111.5% Return on Equity means CASI Pharmaceuticals Inc generated $-1.11 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of CASI Pharmaceuticals Inc:

  • The MRQ is -111.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -111.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-111.5%TTM-111.5%0.0%
TTM-111.5%YOY-88.4%-23.1%
TTM-111.5%5Y-78.4%-33.1%
5Y-78.4%10Y-49.0%-29.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-111.5%-14.2%-97.3%
TTM-111.5%-15.9%-95.6%
YOY-88.4%-14.3%-74.1%
5Y-78.4%-18.5%-59.9%
10Y-49.0%-19.3%-29.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of CASI Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient CASI Pharmaceuticals Inc is operating .

  • Measures how much profit CASI Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare CASI Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -74.6% means the company generated $-0.75  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of CASI Pharmaceuticals Inc:

  • The MRQ is -74.6%. The company is operating very inefficient. -2
  • The TTM is -74.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-74.6%TTM-74.6%0.0%
TTM-74.6%YOY-61.5%-13.2%
TTM-74.6%5Y-249.5%+174.9%
5Y-249.5%10Y-4,364.9%+4,115.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-74.6%-222.9%+148.3%
TTM-74.6%-310.7%+236.1%
YOY-61.5%-223.5%+162.0%
5Y-249.5%-387.1%+137.6%
10Y-4,364.9%-498.5%-3,866.4%
4.3.2.2. Operating Ratio

Measures how efficient CASI Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.80 means that the operating costs are $1.80 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of CASI Pharmaceuticals Inc:

  • The MRQ is 1.796. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.796. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.796TTM1.7960.000
TTM1.796YOY1.615+0.181
TTM1.7965Y3.892-2.097
5Y3.89210Y44.556-40.664
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7962.465-0.669
TTM1.7963.253-1.457
YOY1.6153.298-1.683
5Y3.8924.788-0.896
10Y44.5566.494+38.062
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of CASI Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if CASI Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.55 means the company has $3.55 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of CASI Pharmaceuticals Inc:

  • The MRQ is 3.548. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.548. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.548TTM3.5480.000
TTM3.548YOY4.318-0.770
TTM3.5485Y5.917-2.369
5Y5.91710Y10.028-4.111
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5483.637-0.089
TTM3.5483.890-0.342
YOY4.3184.666-0.348
5Y5.9175.953-0.036
10Y10.0286.277+3.751
4.4.3.2. Quick Ratio

Measures if CASI Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare CASI Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 3.26 means the company can pay off $3.26 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of CASI Pharmaceuticals Inc:

  • The MRQ is 3.264. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.264. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.264TTM3.2640.000
TTM3.264YOY4.030-0.766
TTM3.2645Y5.922-2.658
5Y5.92210Y9.762-3.840
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2643.086+0.178
TTM3.2643.451-0.187
YOY4.0304.456-0.426
5Y5.9225.931-0.009
10Y9.7626.436+3.326
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of CASI Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of CASI Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare CASI Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.68 means that CASI Pharmaceuticals Inc assets are financed with 67.9% credit (debt) and the remaining percentage (100% - 67.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of CASI Pharmaceuticals Inc:

  • The MRQ is 0.679. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.679. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.679TTM0.6790.000
TTM0.679YOY0.304+0.374
TTM0.6795Y0.296+0.383
5Y0.29610Y0.499-0.203
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6790.350+0.329
TTM0.6790.344+0.335
YOY0.3040.310-0.006
5Y0.2960.365-0.069
10Y0.4990.382+0.117
4.5.4.2. Debt to Equity Ratio

Measures if CASI Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare CASI Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 211.5% means that company has $2.11 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of CASI Pharmaceuticals Inc:

  • The MRQ is 2.115. The company is just not able to pay all its debts with equity.
  • The TTM is 2.115. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.115TTM2.1150.000
TTM2.115YOY0.657+1.457
TTM2.1155Y0.710+1.405
5Y0.71010Y0.409+0.301
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1150.394+1.721
TTM2.1150.432+1.683
YOY0.6570.380+0.277
5Y0.7100.451+0.259
10Y0.4090.490-0.081
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings CASI Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare CASI Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -4.11 means the investor is paying $-4.11 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of CASI Pharmaceuticals Inc:

  • The EOD is -1.963. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.109. Based on the earnings, the company is expensive. -2
  • The TTM is -4.109. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.963MRQ-4.109+2.147
MRQ-4.109TTM-4.1090.000
TTM-4.109YOY-0.702-3.407
TTM-4.1095Y-1.426-2.683
5Y-1.42610Y-1.878+0.452
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.963-2.253+0.290
MRQ-4.109-2.411-1.698
TTM-4.109-3.149-0.960
YOY-0.702-3.274+2.572
5Y-1.426-6.143+4.717
10Y-1.878-6.785+4.907
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of CASI Pharmaceuticals Inc:

  • The EOD is -2.381. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.985. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.985. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.381MRQ-4.985+2.604
MRQ-4.985TTM-4.9850.000
TTM-4.985YOY-1.037-3.948
TTM-4.9855Y-1.721-3.264
5Y-1.72110Y-2.682+0.961
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.381-3.009+0.628
MRQ-4.985-3.259-1.726
TTM-4.985-3.730-1.255
YOY-1.037-4.574+3.537
5Y-1.721-8.371+6.650
10Y-2.682-9.287+6.605
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of CASI Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.58 means the investor is paying $4.58 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of CASI Pharmaceuticals Inc:

  • The EOD is 2.188. Based on the equity, the company is underpriced. +1
  • The MRQ is 4.581. Based on the equity, the company is fair priced.
  • The TTM is 4.581. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.188MRQ4.581-2.393
MRQ4.581TTM4.5810.000
TTM4.581YOY0.413+4.168
TTM4.5815Y1.212+3.369
5Y1.21210Y-4.236+5.447
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.1881.979+0.209
MRQ4.5812.051+2.530
TTM4.5812.365+2.216
YOY0.4132.455-2.042
5Y1.2123.726-2.514
10Y-4.2364.378-8.614
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of CASI Pharmaceuticals Inc.

4.8.1. Institutions holding CASI Pharmaceuticals Inc

Institutions are holding 24.223% of the shares of CASI Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30VR Adviser, LLC6.38550.3185987259875573783.9595
2024-09-30Wellington Shields Capital Mgmt LLC0.5770.09558921700
2024-09-30ADAR1 Capital Management LLC0.41930.0656483556595686.8325
2024-09-30Wellington Shields & Co., LLC0.27870.08074309100
2024-09-30Renaissance Technologies Corp0.26840.0004415007001.7157
2024-09-30Woodline Partners LP0.19750.001630532305320
2024-09-30Citadel Advisors Llc0.1469022714227140
2024-09-30Geode Capital Management, LLC0.1252019363-2858-12.8617
2024-09-30UBS Group AG0.095014681336029.6794
2024-09-30Royal Bank of Canada0.04460690000
2024-09-30Morgan Stanley - Brokerage Accounts0.009301440-1440-50
2024-09-30Wells Fargo & Co0.0033050600
2024-06-30BlackRock Inc0.0019029600
2024-09-30West Paces Advisors Inc0.00060.000210000
2024-06-30Bank of America Corp0.000305300
2024-09-30JPMorgan Chase & Co0.000202500
2024-09-30Northwestern Mutual Wealth Management Co0.000101300
2024-09-30Colonial Trust Co / SC0.000101100
2024-09-30Trust Co Of Vermont0.0001010100
2024-06-30Advisor Group Holdings, Inc.0.00010880
Total 8.55410.56191322554+985194+74.5%

4.9.2. Funds holding CASI Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Fidelity Nasdaq Composite Index0.12520.00071936300
2024-06-30NT Quality SCC US Fund - L0.01250.00491931-180-8.5268
2024-09-30JNL/DFA US Small Cap A0.01080.0016166900
2024-09-30Dimensional US Small Cap CIT Class S0.00670.0017103400
2024-10-31Dimensional US Sm Company EUR Acc0.0020.000530610.3279
2024-03-31AZL® DFA US Small Cap0.00090.000214200
Total 0.15810.009624445-179-0.7%

5.3. Insider Transactions

Insiders are holding 47.92% of the shares of CASI Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-09-08James HuangBUY333004.28
2022-09-06James HuangBUY191623.89
2022-08-26James HuangBUY395273.75
2022-08-24James HuangBUY50003.75
2022-08-22James HuangBUY231053.46
2022-08-19James HuangBUY1711163.27
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Net Debt  -51,420-4,352-55,77219,234-36,538-9,230-45,76849,9244,156
Income Tax Expense  6,0469,01015,056-13,1261,930501,980-2,061-81



5.2. Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets75,268
Total Liabilities51,103
Total Stockholder Equity24,165
 As reported
Total Liabilities 51,103
Total Stockholder Equity+ 24,165
Total Assets = 75,268

Assets

Total Assets75,268
Total Current Assets59,344
Long-term Assets15,924
Total Current Assets
Cash And Cash Equivalents 17,083
Short-term Investments 13,686
Net Receivables 10,138
Inventory 15,877
Other Current Assets 2,560
Total Current Assets  (as reported)59,344
Total Current Assets  (calculated)59,344
+/-0
Long-term Assets
Property Plant Equipment 11,633
Long Term Investments 1,681
Intangible Assets 1,839
Long-term Assets Other 766
Long-term Assets  (as reported)15,924
Long-term Assets  (calculated)15,919
+/- 5

Liabilities & Shareholders' Equity

Total Current Liabilities16,726
Long-term Liabilities34,377
Total Stockholder Equity24,165
Total Current Liabilities
Short-term Debt 728
Accounts payable 4,438
Other Current Liabilities 11,079
Total Current Liabilities  (as reported)16,726
Total Current Liabilities  (calculated)16,245
+/- 481
Long-term Liabilities
Long term Debt 18,895
Capital Lease Obligations 2,344
Long-term Liabilities Other 11,821
Long-term Liabilities  (as reported)34,377
Long-term Liabilities  (calculated)33,060
+/- 1,317
Total Stockholder Equity
Common Stock1
Retained Earnings -660,817
Accumulated Other Comprehensive Income -1,200
Other Stockholders Equity 686,181
Total Stockholder Equity (as reported)24,165
Total Stockholder Equity (calculated)24,165
+/-0
Other
Capital Stock1
Cash and Short Term Investments 30,769
Common Stock Shares Outstanding 13,360
Current Deferred Revenue2,543
Liabilities and Stockholders Equity 75,268
Net Debt 4,156
Net Invested Capital 43,060
Net Working Capital 42,618
Property Plant and Equipment Gross 16,284
Short Long Term Debt Total 21,239



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-311997-12-311996-12-311995-12-311994-12-311993-12-311992-12-311991-12-31
> Total Assets 
0
0
0
800
10,100
54,100
47,800
39,600
31,800
31,410
46,218
27,810
40,154
39,404
36,432
55,720
53,015
28,923
10,067
8,037
3,236
8,978
15,508
11,310
5,826
27,713
45,101
113,410
102,631
127,734
138,298
96,234
75,268
75,26896,234138,298127,734102,631113,41045,10127,7135,82611,31015,5088,9783,2368,03710,06728,92353,01555,72036,43239,40440,15427,81046,21831,41031,80039,60047,80054,10010,100800000
   > Total Current Assets 
0
0
0
200
9,400
53,200
45,900
35,600
27,100
26,476
41,992
24,649
38,161
38,243
35,326
54,867
52,258
28,592
9,874
7,928
3,207
8,908
15,411
11,022
5,569
27,449
43,812
92,565
61,501
74,025
61,970
73,423
59,344
59,34473,42361,97074,02561,50192,56543,81227,4495,56911,02215,4118,9083,2077,9289,87428,59252,25854,86735,32638,24338,16124,64941,99226,47627,10035,60045,90053,2009,400200000
       Cash And Cash Equivalents 
0
0
0
200
6,900
33,100
18,200
30,800
26,000
24,504
41,386
24,067
34,812
20,425
11,408
20,896
29,676
16,743
6,312
4,886
1,081
8,049
15,132
10,670
5,131
27,093
43,490
84,205
53,621
57,064
38,704
47,112
17,083
17,08347,11238,70457,06453,62184,20543,49027,0935,13110,67015,1328,0491,0814,8866,31216,74329,67620,89611,40820,42534,81224,06741,38624,50426,00030,80018,20033,1006,900200000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
2,130
14,114
18,675
29,674
18,072
7,548
54
26
0
0
0
0
0
0
0
912
625
9,309
9,868
4,225
13,686
13,6864,2259,8689,309625912000000026547,54818,07229,67418,67514,1142,130000000000000
       Net Receivables 
0
0
0
0
2,500
0
600
300
700
1,478
234
309
691
3,336
4,905
3,919
4,046
3,918
3,287
2,750
1,933
669
0
24
38
34
242
0
1,293
4,645
9,803
12,973
10,138
10,13812,9739,8034,6451,293024234382406691,9332,7503,2873,9184,0463,9194,9053,3366913092341,47870030060002,5000000
       Other Current Assets 
0
0
0
0
0
20,100
27,100
4,500
400
494
371
272
528
367
338
378
464
384
221
266
194
189
280
328
438
356
322
7,448
1,420
1,651
1,688
2,975
2,560
2,5602,9751,6881,6511,4207,4483223564383282801891942662213844643783383675282723714944004,50027,10020,10000000
   > Long-term Assets 
0
0
0
600
700
900
1,900
4,000
4,700
4,934
4,227
3,161
1,993
1,161
1,106
853
757
331
193
109
29
70
96
288
257
264
1,289
20,845
41,130
53,709
76,328
22,811
15,924
15,92422,81176,32853,70941,13020,8451,2892642572889670291091933317578531,1061,1611,9933,1614,2274,9344,7004,0001,900900700600000
       Property Plant Equipment 
0
0
0
600
800
800
1,500
3,000
4,000
4,576
4,186
3,152
1,992
1,150
915
848
620
264
171
105
25
53
78
262
219
230
1,047
1,751
9,693
10,758
21,819
13,229
11,633
11,63313,22921,81910,7589,6931,7511,0472302192627853251051712646208489151,1501,9923,1524,1864,5764,0003,0001,500800800600000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,038
29,442
40,128
7,463
1,681
1,6817,46340,12829,44214,0380000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,785
16,895
13,210
12,203
1,063
1,839
1,8391,06312,20313,21016,89518,785000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
358
41
9
1
11
191
5
136
67
21
5
4
17
18
26
38
34
242
310
504
38,437
2,178
0
0
002,17838,43750431024234382618174521671365191111941358000000000
> Total Liabilities 
0
0
0
600
6,500
6,400
5,700
6,400
9,800
12,353
23,006
17,299
5,278
3,682
7,046
8,739
26,118
23,001
11,993
2,704
704
743
565
11,732
11,914
6,929
6,561
3,948
8,966
24,161
30,339
29,302
51,103
51,10329,30230,33924,1618,9663,9486,5616,92911,91411,7325657437042,70411,99323,00126,1188,7397,0463,6825,27817,29923,00612,3539,8006,4005,7006,4006,500600000
   > Total Current Liabilities 
0
0
0
600
3,700
4,200
4,500
6,400
7,800
11,347
20,734
16,933
4,755
3,263
6,815
8,598
9,328
13,810
11,269
2,704
704
743
565
919
1,054
1,316
5,062
3,874
7,947
7,976
13,186
17,005
16,726
16,72617,00513,1867,9767,9473,8745,0621,3161,0549195657437042,70411,26913,8109,3288,5986,8153,2634,75516,93320,73411,3477,8006,4004,5004,2003,700600000
       Short-term Debt 
0
0
0
0
0
0
0
0
1,100
997
1,006
4,865
0
1,416
61
751
2,982
21
8,555
757
0
0
0
1,390
4
5,614
1,499
1,499
1,182
2,231
1,061
868
728
7288681,0612,2311,1821,4991,4995,61441,3900007578,555212,982751611,41604,8651,0069971,10000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,390
1,465
1,491
1,499
1,499
0
1,292
0
0
0
0001,29201,4991,4991,4911,4651,39000000000000000000000000
       Accounts payable 
0
0
0
600
400
600
700
2,100
4,900
8,563
16,309
10,065
3,953
1,550
5,487
5,909
4,551
11,205
1,969
1,351
453
505
402
755
884
1,065
2,088
968
5,113
3,669
4,789
3,289
4,438
4,4383,2894,7893,6695,1139682,0881,0658847554025054531,3511,96911,2054,5515,9095,4871,5503,95310,06516,3098,5634,9002,100700600400600000
       Other Current Liabilities 
0
0
0
0
3,300
3,600
3,800
4,300
1,800
1,787
1,368
1,892
707
200
228
127
120
2,584
745
595
251
238
163
164
165
251
2,974
1,406
1,652
1,642
6,684
10,798
11,079
11,07910,7986,6841,6421,6521,4062,9742511651641632382515957452,5841201272282007071,8921,3681,7871,8004,3003,8003,6003,3000000
   > Long-term Liabilities 
0
0
0
0
2,800
2,200
1,200
0
2,000
1,006
2,272
366
523
420
230
140
16,790
9,191
724
0
0
0
0
10,813
10,860
5,614
1,499
74
1,019
16,185
17,153
12,297
34,377
34,37712,29717,15316,1851,019741,4995,61410,86010,81300007249,19116,7901402304205233662,2721,0062,00001,2002,2002,8000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,390
1,465
1,491
1,499
0
0
0
0
0
0
0000001,4991,4911,4651,39000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
366
523
419
231
141
21
0
0
0
0
0
0
9,423
9,395
4,122
0
74
0
2,351
17,247
0
0
0017,2472,35107404,1229,3959,4230000002114123141952336600000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,423
0
0
0
0
0
0
0
0
0
0000000009,42300000000000000000000000
> Total Stockholder Equity
0
0
0
300
3,600
47,700
42,000
33,200
22,000
19,040
23,195
10,494
34,859
35,705
29,369
46,963
26,897
5,922
-1,926
5,333
2,532
8,235
14,942
-422
-6,087
20,784
38,540
109,462
72,995
81,540
84,502
44,574
24,165
24,16544,57484,50281,54072,995109,46238,54020,784-6,087-42214,9428,2352,5325,333-1,9265,92226,89746,96329,36935,70534,85910,49423,19519,04022,00033,20042,00047,7003,600300000
   Common Stock
0
0
0
100
100
0
0
0
100
172
218
241
378
436
511
848
857
885
887
115
122
226
271
325
325
603
699
954
979
1,240
1,399
1
1
111,3991,240979954699603325325271226122115887885857848511436378241218172100000100100000
   Retained Earnings Total Equity00-605,6430-523,900-478,941-452,702-441,932-432,478-425,272-399,0700000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-200
-200
-400
-700
-1,500
-2,300
-3,400
-73
-62
-4,325
-5,711
-102
117
67
-58
-6,144
-6,195
-393
-284
-177
-225
-294
-262
-372
-1,226
-2,728
589
1,954
-703
-1,200
-1,200-7031,954589-2,728-1,226-372-262-294-225-177-284-393-6,195-6,144-5867117-102-5,711-4,325-62-73-3,400-2,300-1,500-700-400-200-200000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
421,775
432,559
434,100
470,147
498,577
596,711
606,686
0
694,826
0
0
00694,8260606,686596,711498,577470,147434,100432,559421,7750000000000000000000000
   Treasury Stock00-8,0340-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-7,667-7,667000000000
   Other Stockholders Equity 
0
0
0
13,200
24,200
73,400
74,500
80,000
106,400
153,255
197,347
220,283
268,268
283,064
287,358
354,284
356,671
359,656
359,964
382,290
378,238
401,624
413,918
424,750
426,359
462,375
490,915
588,676
598,652
650,212
686,792
682,436
686,181
686,181682,436686,792650,212598,652588,676490,915462,375426,359424,750413,918401,624378,238382,290359,964359,656356,671354,284287,358283,064268,268220,283197,347153,255106,40080,00074,50073,40024,20013,200000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.